3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Mastocytosis, Systemic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Hairy Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Carcinoma, Medullary
1
Burkitt Lymphoma
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Advanced Cancer
1
Interventions
vandetanib
2
cabozantinib
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Everolimus
2
veliparib
1
vatalanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
temsirolimus
1
sargramostim
1
pentetreotide
1
mercaptoundecahydrododecaborate
1
gallium Ga 68 dotatate
1
fludarabine
1
cixutumumab
1
Vinorelbine
1
Temozolomide
1
Specimen Handling
1
Sirolimus
1
Semaxinib
1
Salts
1
Ranitidine
1
Paclitaxel
1
Omeprazole
1
Octreotide
1
Nivolumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
High-Energy Shock Waves
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Medullary
×
Ranitidine
×
Clear all
NCT01539655
2017-05-02
Vandetanib
Sanofi
Phase 1
Completed
34 enrolled